Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (May 2022)
8 slides from Volitionrx's investor presentation, May 2022
Slide 1: Circulating Nucleosomes as potential prognostic markers for COVID 19 disease severity
Circulating Nucleosomes as potential prognostic markers for COVID 19 disease severity
Slide 2: Purpose-built R&D facility in Belgium
Purpose-built, state of the art, ~20,000 square ft Research and Development facility in Belgium. 3.
Slide 3: Nu.Q-Triage – Risk stratification
Nu.Q™ -Triage – Risk stratification o Colorectal cancer o Lung cancer o Haematological Cancer o COVID-19
Slide 4: Nu.Q - How it works
Nu.Q™- How it works Nu.QTM blood biomarker pipeline falls into 4 main immunoassay categories: 1. Nu.QTM -X specific DNA modifications 2. Nu.QTM -V histone variants Acridinium HRP Reporter ester Detection 3. Nu.QTM -M histone modifications Antibody Nucleosome 4. Nu.QTM -A nucleosome-protein adducts E
Slide 5: Increased NETosis in COVID-19
Increased NETosis in COVID-19 Feedback loop Extracellular o Rapid innate immune response assembly o Bystander effect – e.g. ARDS CXCR2 Fast (0.5-1 hrs) Vital NETosis IL-8* o Hypercoagulation o Capture of CD4+/CD8+ T cells Slow (1-4 hrs) Neutrophil Lytic NETosis o Sepsis like multi organ failure recr
Slide 6: Trial Design and Preliminary Results
Trial Design and Preliminary Results A B 3000 80 n=10 n=25 n=10 n=25 Nu.Q H3R8Cit ng/ml Nu.Q H3.1 ng/ml Nu.Q™ H 3.1 assay 2000 60 • Viral budding 40 1000 • Bystander effects 20 • Apoptotic T cells 0 0 A COVID-19 COVID-19 B • Apoptotic neutrophils SARS Negative SARS Positive COVID-19 COVID-19 COVID-1
Slide 7: Next Steps
Next Steps • Prognostic evaluation in retrospective cohorts (EU and UK) • Prognostic evaluation in longitudinal cohort (EU and UK) • CE marking EU • FDA regulatory Trial (US)
Slide 8: Thank you for your interest in Volition
Thank you for your interest in Volition Mark Eccleston Business Development Director m.eccleston@volitonrx.com www.Volitionrx.com